Latest News

Wednesday, September 20, 2017 | Glaucoma, Aerie Pharmaceuticals

Aerie Pharmaceuticals Announces FDA Advisory Committee Meeting for Rhopressa

Aerie Pharmaceuticals announced that a meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee of the FDA has been scheduled for October 13, 2017 to review the company’s new drug app…

Read the full story

Wednesday, September 20, 2017 | Awards, Prevent Blindness

Prevent Blindness Announces Call for Nominations for 2018 Jenny Pomeroy Award for Excellence in Vision and Public Health

Prevent Blindness is issuing a call for nominations for the 2018 Jenny Pomeroy Award for Excellence in Vision and Public Health. The award recognizes an individual, team, or organization that has made…

Read the full story

Wednesday, September 20, 2017 | Partnerships

Warby Parker and UnitedHealthcare Collaboration to Feature Affordable, Designer Prescription Eyewear

People enrolled in UnitedHealthcare employer-sponsored and individual vision plans can access Warby Parker’s designer prescription eyewear, online or at any of the more than 50 stores nationwide…

Read the full story

Wednesday, September 20, 2017 | Medical Studies

Nerf Guns 'Can Cause Serious Eye Injuries'

Doctors are warning that a toy gun popular with children can cause serious eye injuries. The warning comes after 3 people were treated in an accident and emergency unit after being shot in the eye wit…

Read the full story

Tuesday, September 19, 2017 | Clinical Trials,Retina, AMD, GrayBug

Graybug Vision Initiates Phase 1/2 Trial of GB-102 for Wet AMD

Graybug Vision announced that it has begun dosing patients with wet AMD in its first clinical trial of GB-102, its lead product. GB-102 is a novel intravitreal (IVT) injectable depot formulation of su…

Read the full story

Tuesday, September 19, 2017 | Clinical Trials,Retina, Ophthotech

Ophthotech Provides Update on Zimura Complement Programs for Treatment of Eye Diseases

Ophthotech announced the initiation of an open-label phase 2a clinical trial of Zimura (avacincaptad pegol), the company’s complement factor C5 inhibitor, in patients with wet age-related macula…

Read the full story

Tuesday, September 19, 2017 | Medical Studies,Retina

Laser May Be Safer Than Bevacizumab in Babies With Acute-Phase ROP

Babies with acute-phase retinopathy of prematurity (ROP) who are treated with bevacizumab have more long-term eye problems than babies treated with laser, according to a new randomized controlled tria…

Read the full story

Monday, September 18, 2017 | Acquisitions/Mergers, Johnson & Johnson Vision Care

Johnson & Johnson Vision Acquires Sightbox

Johnson & Johnson Vision continues its fast acquisition pace in 2017 after announcing that it has acquired Sightbox, an online, membership-based subscription service for contact lens wearers in th…

Read the full story

Monday, September 18, 2017 | Product Releases

Swiss Advanced Vision Launches Two EDOF IOLs

Swiss Advanced Vision (SAV-IOL) announced the launch of Lucidis and Eden, two new IOLs that use the Instant Focus EDOF patented technology. According to a company news release, Lucidis brings two majo…

Read the full story

Monday, September 18, 2017 | Acquisitions/Mergers, Alcon, ThromboGenics

ThromboGenics Regains Global Rights to Jetrea (Ocriplasmin)

ThromboGenics announced that it will regain full global rights to Jetrea from Alcon based on a mutual agreement that the unique characteristics of Jetrea make Thrombogenics a better fit for building a…

Read the full story

Monday, September 18, 2017 | Corporate Lawsuits,Patents, Allergan

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

Allergan caused a lot of hand-wringing in the biotech community and excitement among patent lawyers, when the drugmaker announced it would transfer patents for Restasis, Allergan's longstandi…

Read the full story

Monday, September 18, 2017 | Medical Studies

AMD: Brolucizumab Noninferior to Aflibercept in Early Study

Brolucizumab has a comparable efficacy and safety profile to aflibercept among patients with neovascular age-related macular degeneration (AMD), results of a phase 2 study suggest, according to a Meds…

Read the full story

Friday, September 15, 2017 | Miscellaneous, Topcon Medical Systems

Topcon Releases Video Interview Series for Aladdin Biometer

Topcon Medical Systems has announcd the release of a series of video interviews where several Key Opinion Leaders talk about their experiences with the Aladdin Biometer with Corneal Topography and how…

Read the full story

Friday, September 15, 2017 | Awards, Prevent Blindness

Prevent Blindness Names Sue Downes of MyEyeDr as 2018 Person of Vision Award Recipient

Prevent Blindness has chosen Sue Downes, CEO at MyEyeDr., as the recipient of the 2018 Prevent Blindness Person of Vision Award. The award will be presented on March 15, 2018, at the Prevent Blindness…

Read the full story

Friday, September 15, 2017 | Medical Studies

Breakthrough Treatments Arriving for Uveal Melanoma

Not long ago, a diagnosis of uveal melanoma meant losing an eye, if the patient was lucky. In the worst cases, it meant chemotherapy followed by a painful death as the cancer spread. But now, speciali…

Read the full story
Load More
 Stock Price  Change 
 Aerie Pharmaceuticals, Inc. $53.40  -8.87% 
 Akorn, Inc. $33.15  0.15% 
 Alimera Sciences, Inc. $1.33  -0.75% 
 Allergan $210.00  -2.33% 
 Applied Genetic Technologies $3.65  -2.67% 
 Bayer $32.91  -0.72% 
 Can-Fite Biopharma $1.75  4.13% 
 Carl Zeiss Meditec $41.65  -0.82% 
 Clearside Biomedical $7.74  2.38% 
 Cooper Companies, Inc. $236.11  0.05% 
 Eleven Biotherapeutics $1.62  0.62% 
 Escalon Medical Corp. $0.11  0.00% 
 Essilor International $103.85  -1.33% 
 Glaukos $32.75  0.68% 
 Imprimis Pharmaceuticals, Inc. $1.71  4.27% 
 Inotek Pharmaceuticals $1.41  3.68% 
 IRIDEX Corporation $10.25  1.69% 
 Johnson & Johnson $133.22  -1.48% 
 Luxottica Group, S.p.A. $60.90  0.41% 
 Merck & Company, Inc. $65.79  -0.24% 
 NicOx $9.69  3.64% 
 NovaBay Pharmaceuticals, Inc. $4.45  0.00% 
 Novartis AG Common Stock $85.78  -0.08% 
 Ocular Therapeutix $6.31  1.77% 
 Ophthotech Corporation $2.79  9.84% 
 Quantel $6.51  0.00% 
 Regeneron $438.17  1.57% 
 Roche $31.95  0.60% 
 Second Sight Medical Products $1.16  1.75% 
 Shire $153.40  -1.36% 
 Spark Therapeutics, Inc. $87.99  2.53% 
 STAAR Surgical Company $10.95  -0.90% 
 TearLab Corporation $1.35  -2.17% 
 Thrombogenics $3.67  1.97% 
 Valeant Pharmaceuticals $14.07  2.18% 
 Xoma $20.15  6.11%